

# Santos Rd, Santos R

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7114207/publications.pdf>

Version: 2024-02-01

375  
papers

21,082  
citations

23500

58  
h-index

11581

135  
g-index

394  
all docs

394  
docs citations

394  
times ranked

18124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin C and primary prevention of cardiovascular disease: the case for Mendelian randomization. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1838-1839.	0.8	0
2	Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge. <i>Cardiology and Therapy</i> , 2022, 11, 1-7.	1.1	4
3	Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. <i>Journal of Clinical Lipidology</i> , 2022, , .	0.6	0
4	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 32-40.	1.6	19
5	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, e023136.	1.6	8
6	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	6.3	69
7	Prospective associations between multiple lifestyle behaviors and depressive symptoms. <i>Journal of Affective Disorders</i> , 2022, 301, 233-239.	2.0	11
8	Calcified and Noncalcified Coronary Plaques and Atherosclerotic Cardiovascular Events in Patients With Severe Hypercholesterolemia—Moving Forward With Risk Stratification and Therapy. <i>JAMA Network Open</i> , 2022, 5, e2148147.	2.8	2
9	Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study — ELSA-Brasil. <i>Clinics</i> , 2022, 77, 100013.	0.6	1
10	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. <i>Journal of Clinical Lipidology</i> , 2022, , .	0.6	0
11	Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. <i>PLoS ONE</i> , 2022, 17, e0266505.	1.1	3
12	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 363-383.	1.0	7
13	Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2022, 33, 89-94.	1.2	5
14	Screening of <i>ABCG5</i> and <i>ABCG8</i> Genes for Sitosterolemia in a Familial Hypercholesterolemia Cascade Screening Program. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003390.	1.6	8
15	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. <i>Metabolism: Clinical and Experimental</i> , 2022, 132, 155211.	1.5	2
16	Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	3
17	Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment. <i>Liver International</i> , 2022, 42, 1772-1782.	1.9	7
18	Coronary Artery and Thoracic Aorta Calcification and Cardiovascular Events in Severe Hypercholesterolemia: More Wood for the Cardiovascular Disease Risk Heterogeneity Bonfire!. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, .	1.3	2

#	ARTICLE	IF	CITATIONS
19	Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4054.	1.0	10
20	Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. <i>Atherosclerosis Plus</i> , 2022, 49, 47-55.	0.3	1
21	EUROASPIRE V and uncontrolled risk factors in primary prevention: Atherosclerotic cardiovascular disease in the making. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 380-382.	0.8	7
22	Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 385-396.	2.9	15
23	Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 483-495.	0.9	13
24	The Finnish Diabetes Risk Score (FINDRISC), incident diabetes and low-grade inflammation. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108558.	1.1	9
25	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. <i>Endocrinology</i> , 2021, 162, .	1.4	4
26	Familial hypercholesterolemia and cardiovascular disease in older individuals. <i>Atherosclerosis</i> , 2021, 318, 32-37.	0.4	12
27	Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 272-279.	0.8	7
28	Posicionamento sobre o Consumo de Gorduras e SaÃºde Cardiovascular â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 160-212.	0.3	21
29	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1267-1275.	0.9	3
30	Past, Present, and Future of Familial Hypercholesterolemia Management. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 28-35.	0.5	9
31	Addressing Gaps in Racial/Ethnic Representation in Familial Hypercholesterolemia Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007306.	0.9	5
32	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021, 23, 17.	2.0	41
33	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.4	11
34	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health â€“ ELSA-Brasil. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108747.	1.1	8
35	PercepÃ§Ã£o Inadequada do Risco Cardiovascular e Baixo Conhecimento sobre Hipercolesterolemia Familiar em IndivÃduos com Hipercolesterolemia Grave. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 706-712.	0.3	7
36	Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk. <i>Atherosclerosis</i> , 2021, 324, 1-8.	0.4	3

#	ARTICLE	IF	CITATIONS
37	From the President of the International Atherosclerosis Society: The Iraqi Lipid Clinics Network. <i>Journal of Clinical Lipidology</i> , 2021, 15, 538-539.	0.6	0
38	Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2792-2795.	1.2	3
39	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 40.	2.0	15
40	Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2014-2022.	1.1	27
41	Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. <i>Current Cardiology Reports</i> , 2021, 23, 83.	1.3	6
42	Incidence and associated factors of type 2 diabetes mellitus onset in the Brazilian HIV/AIDS cohort study. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101608.	0.3	4
43	Reference values for the triglyceride to high-density lipoprotein ratio and its association with cardiometabolic diseases in a mixed adult population: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2021, 15, 699-711.	0.6	6
44	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
45	Coronary Artery Calcification and Risk Stratification in Familial Hypercholesterolemia. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2425-2428.	2.3	2
46	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9378.	1.8	7
47	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	11
48	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	6.3	142
49	AtualizaÃ§Ã£o da Diretriz Brasileira de Hipercolesterolemia Familiar â€ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 782-844.	0.3	10
50	Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. <i>Atherosclerosis Plus</i> , 2021, 43, 3-6.	0.3	9
51	Updates on genetics and molecular biology. <i>Current Opinion in Lipidology</i> , 2021, 32, 333-334.	1.2	0
52	COVID-19 and Thromboinflammation: Is There a Role for Statins?. <i>Clinics</i> , 2021, 76, e2518.	0.6	9
53	Preventing the Next Pandemic: The Case for Investing in Circulatory Health â€ A Global Coalition for Circulatory Health Position Paper. <i>Global Heart</i> , 2021, 16, 66.	0.9	6
54	Management of Homozygous Familial Hypercholesterolemia. <i>Contemporary Cardiology</i> , 2021, , 383-404.	0.0	0

#	ARTICLE	IF	CITATIONS
55	OUP accepted manuscript. European Journal of Preventive Cardiology, 2021, , .	0.8	0
56	Physical Activity and HDL-C: Are There Gender Differences in the Dose-response Effect?. Arquivos Brasileiros De Cardiologia, 2021, 117, 501-502.	0.3	0
57	Advancing Prediction of Pathogenicity of Familial Hypercholesterolemia LDL Receptor Commonest Variants With Machine Learning Models. JACC Basic To Translational Science, 2021, 6, 828-830.	1.9	4
58	Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion. Journal of Clinical Lipidology, 2021, 15, 620-624.	0.6	3
59	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	1.1	38
60	Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies. Frontiers in Cardiovascular Medicine, 2021, 8, 788062.	1.1	9
61	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	12
62	The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International Cholesterol management Practice Study. European Journal of Preventive Cardiology, 2020, 27, 1403-1411.	0.8	17
63	Bringing interleukin-6 complexity to preventive cardiology practice?. European Journal of Preventive Cardiology, 2020, 27, 119-121.	0.8	1
64	Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. European Heart Journal Cardiovascular Imaging, 2020, 21, 251-257.	0.5	16
65	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology, 2020, 5, 217.	3.0	169
66	Absence of coronary artery calcification and low rates not only of coronary and cardiovascular mortality: Can the power of zero be expanded beyond the vessels?. Atherosclerosis, 2020, 294, 44-45.	0.4	1
67	Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease. European Journal of Preventive Cardiology, 2020, 27, 1606-1616.	0.8	45
68	Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2020, 13, 1090-1092.	2.3	34
69	Very high LDL cholesterol: The power of zero passes another test. Atherosclerosis, 2020, 292, 207-208.	0.4	8
70	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis, 2020, 293, 49-56.	0.4	21
71	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.4	4
72	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.4	21

#	ARTICLE	IF	CITATIONS
73	Coronary Artery Calcification in Familial Hypercholesterolemia. <i>Circulation</i> , 2020, 142, 1405-1407.	1.6	23
74	Metabolic health in Brazil: trends and challenges. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 937-938.	5.5	10
75	The Role of Statins in Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2020, 22, 50.	2.0	17
76	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. <i>Journal of Lipid Research</i> , 2020, 61, 1254-1262.	2.0	25
77	From the President of the International Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2020, 14, 613-614.	0.6	0
78	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 1317-1327.	13.9	108
79	The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100097.	1.3	10
80	Does physical activity influence the association between depressive symptoms and low-grade inflammation in adults? A study of 8,048 adults. <i>Physiology and Behavior</i> , 2020, 223, 112967.	1.0	10
81	Self-initiated changes in physical activity and incidence of Metabolic Syndrome: A longitudinal follow-up study. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108224.	1.1	4
82	Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey. <i>Lipids in Health and Disease</i> , 2020, 19, 131.	1.2	5
83	Association of Omnivorous and Vegetarian Diets With Antioxidant Defense Mechanisms in Men. <i>Journal of the American Heart Association</i> , 2020, 9, e015576.	1.6	13
84	The contribution of the systolic and diastolic components for the diagnosis of arterial hypertension under the 2017 ACC/AHA Guideline and metabolic heterogeneity among individuals with Stage 1 hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1192-1199.	1.0	6
85	Relationship between TSH Levels and the Advanced Lipoprotein Profile in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Endocrine Research</i> , 2020, 45, 163-173.	0.6	1
86	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 565-574.	1.2	126
87	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020, 17, 360-377.	6.1	82
88	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020, 16, 177-189.	4.3	790
89	Risco Cardiovascular e Elegibilidade Para Estatina na Prevenção Primária: Comparação Entre a Diretriz Brasileira e a Diretriz da AHA/ACC. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 440-449.	0.3	5
90	Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 472-482.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Menor Prevalência e Extensão da Aterosclerose Coronária na Doença de Chagas Crônica por Angiotomografia Coronária. Arquivos Brasileiros De Cardiologia, 2020, 115, 1051-1060.	0.3	4
92	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2508-2515.	1.1	15
93	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4114-4116.	1.8	6
94	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. Journal of Clinical Lipidology, 2019, 13, 735-743.	0.6	1
95	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes and Endocrinology, 2019, 7, 715-725.	5.5	687
96	Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study. Social Science and Medicine, 2019, 242, 112591.	1.8	13
97	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Progress in Cardiovascular Diseases, 2019, 62, 414-422.	1.6	34
98	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. Archives of Medical Research, 2019, 50, 362-367.	1.5	14
99	Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries. European Journal of Clinical Nutrition, 2019, 73, 1622-1625.	1.3	7
100	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. Journal of Clinical Lipidology, 2019, 13, 804-811.e2.	0.6	10
101	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis, 2019, 282, 110-120.	0.4	68
102	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\pm$ ) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
103	Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International Cholesterol management Practice Study. Journal of Clinical Lipidology, 2019, 13, 594-600.	0.6	17
104	Residual vascular risk in diabetes—Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	1.8	4
105	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. Advances in Therapy, 2019, 36, 1786-1811.	1.3	35
106	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 286, 40-45.	0.4	7
107	Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency. Journal of Clinical Lipidology, 2019, 13, 468-480.e8.	0.6	16
108	Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America. Clínica E Investigación En Arteriosclerosis (English Edition), 2019, 31, 15-22.	0.1	0



#	ARTICLE	IF	CITATIONS
109	Baseline LDL-C levels and risk of cardiovascular events: is there any room for questions?. International Journal of Cardiology, 2019, 286, 166-167.	0.8	0
110	Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Journal of Clinical Lipidology, 2019, 13, 397-401.	0.6	17
111	Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". Journal of Clinical Lipidology, 2019, 13, 287-300.	0.6	32
112	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy, 2019, 33, 69-76.	1.3	11
113	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. European Journal of Preventive Cardiology, 2019, 26, 820-823.	0.8	8
114	Lomitapide and Mipomersen "Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Current Atherosclerosis Reports, 2019, 21, 48.	2.0	36
115	Update on genetics and molecular biology. Current Opinion in Lipidology, 2019, 30, 414-416.	1.2	0
116	Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Current Opinion in Lipidology, 2019, 30, 82-87.	1.2	9
117	SPPARM alpha. Current Opinion in Lipidology, 2019, 30, 419-427.	1.2	11
118	Screening and management of familial hypercholesterolemia. Current Opinion in Cardiology, 2019, 34, 526-530.	0.8	15
119	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 280, 109-117.	0.4	40
120	Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. JACC: Cardiovascular Imaging, 2019, 12, 1797-1804.	2.3	106
121	Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH. Atherosclerosis, 2019, 281, 145-147.	0.4	1
122	Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America. Clínica E Investigación En Arteriosclerosis, 2019, 31, 15-22.	0.4	4
123	Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. American Journal of Cardiology, 2018, 121, 1315-1320.	0.7	4
124	Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 481-483.	1.1	11
125	Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. Journal of Clinical Lipidology, 2018, 12, 685-692.e2.	0.6	35
126	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Journal of Clinical Lipidology, 2018, 12, 958-965.	0.6	44



#	ARTICLE	IF	CITATIONS
127	Obstructive sleep apnea and effects of continuous positive airway pressure on triglyceride-rich lipoprotein metabolism. <i>Journal of Lipid Research</i> , 2018, 59, 1027-1033.	2.0	30
128	Self-initiated physical activity is associated with high sensitivity C-reactive protein: A longitudinal study in 5,030 adults. <i>Atherosclerosis</i> , 2018, 273, 131-135.	0.4	27
129	Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation. <i>Clinical Cardiology</i> , 2018, 41, 28-33.	0.7	8
130	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
131	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
132	Low-density lipoprotein cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?. <i>Clinical Cardiology</i> , 2018, 41, 333-338.	0.7	2
133	The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol <70 mg/dL: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Atherosclerosis</i> , 2018, 274, 61-66.	0.4	8
134	Health literacy in familial hypercholesterolemia: A cross-national study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 936-943.	0.8	36
135	The relationship between migraine and lipid sub-fractions among individuals without cardiovascular disease: A cross-sectional evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Cephalalgia</i> , 2018, 38, 528-542.	1.8	9
136	Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 741-746.	1.4	9
137	Safety of statin treatment in children with familial hypercholesterolemia: Filling the gaps. <i>Journal of Clinical Lipidology</i> , 2018, 12, 12-15.	0.6	2
138	Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 303-308.	0.3	4
139	Mendelian randomization causally link lipoproteins to systemic atherosclerosis and help design clinical trials for the future of lipidology. <i>Current Opinion in Lipidology</i> , 2018, 29, 482-483.	1.2	2
140	Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil. <i>Atherosclerosis</i> , 2018, 277, 464-469.	0.4	5
141	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.4	6
142	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
143	Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 277, 493-501.	0.4	18
144	Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil. <i>Atherosclerosis</i> , 2018, 277, 273-277.	0.4	22

#	ARTICLE	IF	CITATIONS
145	Impact of self-reported fasting duration on lipid profile variability, cardiovascular risk stratification and metabolic syndrome diagnosis. Archives of Endocrinology and Metabolism, 2018, 62, 187-192.	0.3	2
146	ClinVar database of global familial hypercholesterolemia-associated DNA variants. Human Mutation, 2018, 39, 1631-1640.	1.1	84
147	Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. European Thyroid Journal, 2018, 7, 302-307.	1.2	17
148	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetes and Vascular Disease Research, 2018, 15, 541-547.	0.9	6
149	Cholesterol and inflammation: The lesser the better in atherothrombosis. European Journal of Preventive Cardiology, 2018, 25, 944-947.	0.8	13
150	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International Cholesterol management Practice Study (ICLPS). European Journal of Preventive Cardiology, 2018, 25, 1087-1094.	0.8	86
151	Heterozygous Familial Hypercholesterolaemia in Specialist Centres in South Africa, Australia and Brazil: Importance of Early Detection and Lifestyle Advice. Atherosclerosis Supplements, 2018, 32, 6.	1.2	0
152	Underdiagnosis, Undertreatment and Cardiovascular Risk Misperception among Individuals with Suspected Familial Hypercholesterolemia: a Brazilian Survey. Atherosclerosis Supplements, 2018, 32, 48.	1.2	0
153	Characterization of Elderly Individuals with Familial Hypercholesterolemia. Atherosclerosis Supplements, 2018, 32, 80.	1.2	0
154	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. Journal of Clinical Lipidology, 2018, 12, 1290-1297.e1.	0.6	10
155	Beware of early drug intolerance in secondary prevention of cardiovascular disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 202-204.	1.4	0
156	Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 72, 662-680.	1.2	387
157	Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids in Health and Disease, 2018, 17, 25.	1.2	9
158	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Journal of Clinical Lipidology, 2018, 12, 1234-1243.e5.	0.6	40
159	Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia. Arquivos Brasileiros De Cardiologia, 2018, 111, 578-584.	0.3	3
160	Reduced subclinical carotid vascular disease and arterial stiffness in vegetarian men: The CARVOS Study. International Journal of Cardiology, 2017, 230, 562-566.	0.8	31
161	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIC study. Lancet Diabetes and Endocrinology, the, 2017, 5, 280-290.	5.5	191
162	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). American Journal of Cardiology, 2017, 119, 1352-1358.	0.7	26

#	ARTICLE	IF	CITATIONS
163	Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.	1.6	270
164	Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study. <i>Atherosclerosis</i> , 2017, 263, 393-397.	0.4	27
165	Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?. <i>Current Opinion in Lipidology</i> , 2017, 28, 130-135.	1.2	16
166	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. <i>Atherosclerosis</i> , 2017, 263, 112-118.	0.4	4
167	Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?. <i>Atherosclerosis</i> , 2017, 263, 316-317.	0.4	2
168	Lipoprotein(a) and cardiovascular mortality: mystery still unsolved. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 489-490.	5.5	2
169	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
170	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
171	Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin/kexin type 9 inhibitor clinical trials. <i>Current Opinion in Lipidology</i> , 2017, 28, 522-523.	1.2	5
172	Computed tomography angiography defined vulnerable plaque in a patient with low high-density lipoprotein cholesterol and subsequent myocardial infarction. <i>Coronary Artery Disease</i> , 2017, 28, 712-714.	0.3	0
173	Neutrophil to lymphocyte ratio and abdominal aortic atherosclerosis among asymptomatic individuals. <i>Atherosclerosis</i> , 2017, 263, e201.	0.4	1
174	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17093.	18.1	315
175	Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil. <i>Atherosclerosis</i> , 2017, 263, 257-262.	0.4	25
176	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. <i>Current Medical Research and Opinion</i> , 2017, 33, 239-251.	0.9	18
177	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 7-32.	1.0	41
178	Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. <i>Journal of Clinical Lipidology</i> , 2017, 11, 160-166.	0.6	23
179	Better health literacy can make the difference when control of risk factors for cardiovascular disease and quality of life are concerned. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1878-1879.	0.8	6
180	Association of subclinical inflammation, glycated hemoglobin and risk for obstructive sleep apnea syndrome. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 136-140.	0.3	1

#	ARTICLE	IF	CITATIONS
181	Metabolic syndrome, diabetes and inadequate lifestyle in first-degree relatives of acute myocardial infarction survivors younger than 45 years old. <i>Lipids in Health and Disease</i> , 2017, 16, 224.	1.2	2
182	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 53.	1.2	34
183	Subclinical carotid vascular disease and risk factors for atherosclerosis in type 1 and type 2 diabetes. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 105-107.	0.3	2
184	Self-Reported High-Cholesterol Prevalence in the Brazilian Population: Analysis of the 2013 National Health Survey. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 411-416.	0.3	14
185	Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 508-517.	0.3	6
186	The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 518-525.	0.3	3
187	Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf. <i>Current Vascular Pharmacology</i> , 2016, 14, 374-381.	0.8	6
188	Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 891-900.	0.9	36
189	Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study. <i>Nutrition and Metabolism</i> , 2016, 13, 37.	1.3	25
190	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
191	Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2016, 164, JC31.	2.0	6
192	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>American Heart Journal</i> , 2016, 178, 135-144.	1.2	58
193	Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf. <i>Journal of Clinical Lipidology</i> , 2016, 10, 368-377.	0.6	14
194	Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 250, 144-150.	0.4	19
195	Familial hypercholesterolaemia: beware of lipoprotein(a). <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 553-555.	5.5	8
196	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1011-1021.	0.6	104
197	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1647-1650.	1.1	23
198	Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 254, 73-77.	0.4	9

#	ARTICLE	IF	CITATIONS
199	Dyslipidemia according to gender and race: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2016, 10, 1362-1368.	0.6	21
200	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Clinical Cardiology</i> , 2016, 39, 215-222.	0.7	5
201	Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 49.	1.2	2
202	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	5.5	329
203	Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 531-537.	0.2	2
204	Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Clinical Lipidology</i> , 2016, 10, 568-576.	0.6	30
205	Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. <i>Atherosclerosis</i> , 2016, 248, 62-75.	0.4	42
206	Extremely elevated HDL-cholesterol levels are not associated with increased carotid intima-media thickness: data from ELSA Brasil. <i>Journal of Clinical Lipidology</i> , 2016, 10, 898-904.e1.	0.6	7
207	Homozygous familial hypercholesterolemia: phenotype rules!. <i>Atherosclerosis</i> , 2016, 248, 252-254.	0.4	3
208	PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 377-379.	5.5	5
209	Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2016, 248, 76-83.	0.4	74
210	Association between a healthy cardiovascular risk factor profile and coronary artery calcium score: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>American Heart Journal</i> , 2016, 174, 51-59.	1.2	32
211	ACC/AHA guidelines determining statin eligibility better predicted CVD than ATP-III guidelines. <i>Annals of Internal Medicine</i> , 2015, 163, JC11.	2.0	0
212	Cascade Screening in Familial Hypercholesterolemia: Advancing Forward. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 869-880.	0.9	20
213	Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. <i>Journal of Hypertension</i> , 2015, 33, 1207-1214.	0.3	90
214	Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. <i>Current Vascular Pharmacology</i> , 2015, 13, 759-770.	0.8	25
215	Obesity and Metabolic Phenotypes (Metabolically Healthy and Unhealthy Variants) Are Significantly Associated with Prevalence of Elevated C-Reactive Protein and Hepatic Steatosis in a Large Healthy Brazilian Population. <i>Journal of Obesity</i> , 2015, 2015, 1-6.	1.1	44
216	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024

#	ARTICLE	IF	CITATIONS
217	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 689-699.	1.1	165
218	Europe aspires to set the record straight on familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2015, 241, 769-771.	0.4	7
219	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	0.8	60
220	The Agenda for Familial Hypercholesterolemia. <i>Circulation</i> , 2015, 132, 2167-2192.	1.6	539
221	Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: The perception gap. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1076-1082.	0.8	40
222	Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 1254-1261.	1.2	46
223	Fatty liver, inflamed blood and calcified coronary arteries: Lessons and uncertainties from the multiethnic study of atherosclerosis -commentary on the study of Al Rifai etÂal.. <i>Atherosclerosis</i> , 2015, 239, 634-636.	0.4	1
224	Peripheral arterial disease in heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2015, 242, 174-178.	0.4	26
225	Apolipoprotein AI Deficiency Inhibits Serum Opacity Factor Activity against Plasma High Density Lipoprotein via a Stabilization Mechanism. <i>Biochemistry</i> , 2015, 54, 2295-2302.	1.2	5
226	Recommendations for the Management of Patients with Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 473.	2.0	13
227	Mipomersen preferentially reduces small low-density lipoprotein particle number inÂpatients with hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2015, 9, 201-209.	0.6	26
228	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
229	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.4	148
230	Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. <i>Journal of Lipid Research</i> , 2015, 56, 703-712.	2.0	73
231	Obesity Modifies the Effect of Fitness on Heart Rate Indices during Exercise Stress Testing in Asymptomatic Individuals. <i>Cardiology</i> , 2015, 132, 242-248.	0.6	1
232	Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. <i>European Heart Journal</i> , 2015, 36, 566-575.	1.0	114
233	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). <i>Journal of Clinical Lipidology</i> , 2015, 9, 676-683.	0.6	14
234	Relation of Physical Activity to Prevalence of Nonalcoholic Fatty Liver Disease Independent of Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2015, 115, 34-39.	0.7	25



#	ARTICLE	IF	CITATIONS
235	Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects. <i>Atherosclerosis</i> , 2015, 238, 101-107.	0.4	75
236	Familial hypercholesterolaemia: PCSK9 inhibitors are coming. <i>Lancet, The</i> , 2015, 385, 307-310.	6.3	29
237	Low HDL cholesterol but not high LDL cholesterol is independently associated with subclinical coronary atherosclerosis in healthy octogenarians. <i>Aging Clinical and Experimental Research</i> , 2015, 27, 61-67.	1.4	14
238	Pericardial Fat Is Associated with Coronary Artery Calcification in Non-Dialysis Dependent Chronic Kidney Disease Patients. <i>PLoS ONE</i> , 2014, 9, e114358.	1.1	7
239	The prevalence of the metabolically healthy obese phenotype in an aging population and its association with subclinical cardiovascular disease: The Brazilian study on healthy aging. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 121.	1.2	6
240	Liver histology during Mipomersen therapy for severe hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 606-611.	0.6	45
241	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
242	CXCR3 Controls T-Cell Accumulation in Fat Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1374-1381.	1.1	29
243	Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome. <i>Journal of Lipid Research</i> , 2014, 55, 2509-2520.	2.0	31
244	What is new in familial hypercholesterolemia?. <i>Current Opinion in Lipidology</i> , 2014, 25, 183-188.	1.2	23
245	The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 548-555.	0.7	16
246	Delayed Heart Rate Recovery is Strongly Associated With Early and Late-Stage Prehypertension During Exercise Stress Testing. <i>American Journal of Hypertension</i> , 2014, 27, 514-521.	1.0	23
247	Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2014, 45, 52-57.	1.5	15
248	Testosterone: A vascular hormone? Commentary on the study of Vlachopoulos etÂal.. <i>Atherosclerosis</i> , 2014, 233, 559-560.	0.4	0
249	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	0.6	98
250	Lipoprotein(a) and Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1990-1991.	1.2	10
251	Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. <i>BMC Public Health</i> , 2014, 14, 14.	1.2	250
252	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149



#	ARTICLE	IF	CITATIONS
253	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
254	What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?. <i>Atherosclerosis Supplements</i> , 2014, 15, 19-25.	1.2	7
255	Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 79.	1.2	25
256	Non Alcoholic Fatty Liver: Should We Care?. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	1
257	C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 19-23.	1.4	12
258	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Atherosclerosis</i> , 2014, 232, 410-413.	0.4	36
259	Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2014, 233, 206-210.	0.4	55
260	Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects. <i>Atherosclerosis</i> , 2014, 233, 319-325.	0.4	16
261	Association between postprandial triglycerides and coronary artery disease detected by coronary computed tomography angiography. <i>Atherosclerosis</i> , 2014, 233, 381-386.	0.4	17
262	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
263	Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2014, 113, 637-643.	0.7	52
264	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
265	Association of Peripheral Arterial and Cardiovascular Diseases in Familial Hypercholesterolemia. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 118-23.	0.3	15
266	Commentary on "Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players". <i>Southern Medical Journal</i> , 2014, 107, 640-641.	0.3	0
267	Family history of coronary heart disease and markers of subclinical cardiovascular disease: Where do we stand?. <i>Atherosclerosis</i> , 2013, 228, 285-294.	0.4	32
268	Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1061-1064.	1.5	18
269	Extensive Xanthomas and Severe Subclinical Atherosclerosis in Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2193.	1.2	10
270	Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 551-555.	1.3	8

#	ARTICLE	IF	CITATIONS
271	ELEVATED GAMMA-GLUTAMYL TRANSFERASE IS INDEPENDENTLY ASSOCIATED WITH BURDEN OF SUBCLINICAL VASCULAR INFLAMMATION. <i>Journal of the American College of Cardiology</i> , 2013, 61, E1331.	1.2	1
272	Plaque regression measured by intravascular ultrasound and reduction of cardiovascular events: Not yet the case, commentary on the study of D'Ascenzo etÁal.. <i>Atherosclerosis</i> , 2013, 226, 45-46.	0.4	0
273	Lipid-lowering treatment for homozygous familial hypercholesterolaemia. <i>Lancet, The</i> , 2013, 381, 1182.	6.3	3
274	Validating the benefits of lipid modifying therapies upon atherosclerotic plaque by computed tomography angiography: Should we trust our eyes? Commentary on the study of Zeb etÁal.. <i>Atherosclerosis</i> , 2013, 231, 189-190.	0.4	0
275	Statin restores cardiac autonomic response to acute hypoxia in hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1291-1298.	1.7	5
276	Angiotensinogen gene polymorphism and HDL2 are linked to coronary artery calcification in individuals with family history of early coronary disease. <i>Atherosclerosis</i> , 2013, 226, 339-340.	0.4	1
277	A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?. <i>Atherosclerosis</i> , 2013, 230, 258-267.	0.4	301
278	Relation of Hepatic Steatosis to Atherogenic Dyslipidemia. <i>American Journal of Cardiology</i> , 2013, 112, 1599-1604.	0.7	17
279	Impact of Fitness Versus Obesity on Routinely Measured Cardiometabolic Risk in Young, Healthy Adults. <i>American Journal of Cardiology</i> , 2013, 111, 991-995.	0.7	10
280	Atorvastatin Treatment Improves Myocardial and Peripheral Blood Flow in Familial Hypercholesterolemia Subjects without Evidence of Coronary Atherosclerosis. <i>Echocardiography</i> , 2013, 30, 64-71.	0.3	13
281	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132
282	Imaging biomarkers to track subclinical atherosclerosis in heterozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 231-242.	0.4	2
283	Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis?. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 320-326.	0.3	18
284	RelevÃncia da prÃ©-hipertensÃ£o como categoria diagnÃ³stica em adultos assintomÃ¡ticos. <i>Einstein (Sao) Tj ETQq0 0 0 rgBT /Overloc</i>	0.3	11
285	Increased resting heart rate and greater progression of subclinical coronary atherosclerosis: Another bad fact about fast hearts? Commentary on the study of Rubin et al.. <i>Atherosclerosis</i> , 2012, 220, 36-37.	0.4	1
286	Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. <i>Atherosclerosis</i> , 2012, 221, 131-136.	0.4	47
287	The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions. <i>Atherosclerosis</i> , 2012, 221, 268-274.	0.4	11
288	Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. <i>Atherosclerosis</i> , 2012, 223, 262-268.	0.4	285

#	ARTICLE	IF	CITATIONS
289	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2. <i>Atherosclerosis</i> , 2012, 224, 150-153.	0.4	35
290	Non-alcoholic fatty liver disease and cardiovascular disease. <i>Atherosclerosis</i> , 2012, 224, 324-325.	0.4	12
291	Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. <i>Clinica Chimica Acta</i> , 2012, 413, 502-505.	0.5	24
292	Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis. <i>American Journal of Cardiology</i> , 2012, 110, 1787-1792.	0.7	65
293	Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander?. <i>Endocrine</i> , 2012, 41, 350-352.	1.1	20
294	Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients <65 Years Versus Patients ≥65 Years (from the Lipid Treatment Assessment Project [L-TAP] 2). <i>American Journal of Cardiology</i> , 2012, 109, 1738-1742.	0.7	5
295	The association between coronary artery calcification progression and loss of bone density in non-dialyzed CKD patients. <i>Clinical Nephrology</i> , 2012, 78, 425-431.	0.4	8
296	The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. <i>Annals of Medicine</i> , 2011, 43, 487-494.	1.5	19
297	Severe Periodontitis Is Associated With Diastolic Blood Pressure Elevation in Individuals With Heterozygous Familial Hypercholesterolemia: A Pilot Study. <i>Journal of Periodontology</i> , 2011, 82, 683-688.	1.7	24
298	Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. <i>Journal of Clinical Lipidology</i> , 2011, 5, 124-132.	0.6	4
299	Guideline for minimizing radiation exposure during acquisition of coronary artery calcium scans with the use of multidetector computed tomography. <i>Journal of Cardiovascular Computed Tomography</i> , 2011, 5, 75-83.	0.7	96
300	Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2). <i>American Journal of Cardiology</i> , 2011, 107, 1639-1643.	0.7	7
301	Is Coronary Artery Calcification Associated with Vertebral Bone Density in Nondialyzed Chronic Kidney Disease Patients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1456-1462.	2.2	20
302	Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1927-1932.	1.1	144
303	LDL Targeted Therapies. , 2011, , 605-619.		0
304	Marked HDL deficiency and premature coronary heart disease. <i>Current Opinion in Lipidology</i> , 2010, 21, 289-297.	1.2	106
305	Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 35.	1.2	14
306	Relation of Aortic Valve Calcium Detected by Cardiac Computed Tomography to All-Cause Mortality. <i>American Journal of Cardiology</i> , 2010, 106, 1787-1791.	0.7	55

#	ARTICLE	IF	CITATIONS
307	Pre-historic eating patterns in Latin America and protective effects of plant-based diets on cardiovascular risk factors. <i>Clinics</i> , 2010, 65, 1049-1054.	0.6	15
308	Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: case-control study. <i>Sao Paulo Medical Journal</i> , 2010, 128, 137-140.	0.4	29
309	Plasma cholesterol is involved in the setting of resting blood pressure: A study in hypercholesterolemic young subjects and in monozygotic twins. <i>International Journal of Cardiology</i> , 2010, 144, 88-89.	0.8	0
310	Thoracic aorta calcification detected by electron beam tomography predicts all-cause mortality. <i>Atherosclerosis</i> , 2010, 209, 131-135.	0.4	87
311	Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. <i>Atherosclerosis</i> , 2010, 209, 481-486.	0.4	70
312	Persistency of depression is associated with subclinical coronary atherosclerosis in males: Commentary on the study of Hamer et al.. <i>Atherosclerosis</i> , 2010, 210, 41-42.	0.4	0
313	Coronary artery calcification progression and cardiovascular events in renal transplant recipients, bad inheritance from previous kidney disease: Commentary on the study of Roe et al.. <i>Atherosclerosis</i> , 2010, 212, 390-391.	0.4	3
314	Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2010, 213, 486-491.	0.4	68
315	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	6.3	813
316	Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. <i>Current Medical Research and Opinion</i> , 2010, 26, 2589-2597.	0.9	17
317	High Density Lipoproteins, Dyslipidemia, and Heart Disease: Past, Present, and Future. , 2010, , 181-199.		0
318	Human Apolipoprotein A-I Deficiency. , 2010, , 55-61.		0
319	Uric Acid and Cardiovascular Disease: How to Solve Another Chicken or Egg Puzzle. <i>Cardiology</i> , 2009, 114, 298-299.	0.6	5
320	Lipid Treatment Assessment Project 2. <i>Circulation</i> , 2009, 120, 28-34.	1.6	293
321	Coronary Artery Calcification and Inflammation According to Various Metabolic Syndrome Definitions. <i>Journal of the Cardiometabolic Syndrome</i> , 2009, 4, 33-39.	1.7	4
322	Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. <i>American Heart Journal</i> , 2009, 158, 860-866.	1.2	40
323	Coronary calcification and coronary heart disease death rates in different countries, not only the influence of classical risk factors. <i>Atherosclerosis</i> , 2009, 202, 32-33.	0.4	6
324	Uric acid: A marker of increased cardiovascular risk. <i>Atherosclerosis</i> , 2009, 202, 11-17.	0.4	310

#	ARTICLE	IF	CITATIONS
325	Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes. <i>Atherosclerosis</i> , 2009, 204, 165-170.	0.4	22
326	Commentary on the study of Laatsch et al. "Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance". <i>Atherosclerosis</i> , 2009, 204, 112-113.	0.4	1
327	Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?. <i>Atherosclerosis</i> , 2009, 205, 349-356.	0.4	37
328	Commentary on the study of Rivera et al.: The relation of risk factors and total coronary artery plaque burden evaluated by multi-detector row computed tomography angiography. <i>Atherosclerosis</i> , 2009, 206, 349-350.	0.4	0
329	A obesidade e sua associaÃ§Ã£o com os demais fatores de risco cardiovascular em escolares de Itapetinga, Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 93, 253-60.	0.3	34
330	Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. <i>American Journal of Kidney Diseases</i> , 2008, 52, 1139-1150.	2.1	112
331	The Metabolic Syndrome Adds Incremental Value to the Framingham Risk Score in Identifying Asymptomatic Individuals With Higher Degrees of Inflammation. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 7-11.	1.7	3
332	Favorable Cardiovascular Risk Factor Profile Is Associated With Reduced Prevalence of Coronary Artery Calcification and Inflammation in Asymptomatic Nondiabetic White Men. <i>Preventive Cardiology</i> , 2008, 11, 189-194.	1.1	8
333	Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein "deficiency states. <i>Journal of Clinical Lipidology</i> , 2008, 2, 237-247.	0.6	35
334	Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. <i>Atherosclerosis</i> , 2008, 197, 910-915.	0.4	40
335	No correlation and low agreement of imaging and inflammatory atherosclerosis " markers in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 200, 83-88.	0.4	47
336	A synergistic relationship of elevated low-density lipoprotein cholesterol levels and systolic blood pressure with coronary artery calcification. <i>Atherosclerosis</i> , 2008, 200, 368-373.	0.4	1
337	Phosphate Binder Impact on Bone Remodeling and Coronary Calcification " Results from the BRIC Study. <i>Nephron Clinical Practice</i> , 2008, 110, c273-c283.	2.3	146
338	Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. <i>Journal of Lipid Research</i> , 2008, 49, 349-357.	2.0	57
339	Pulse wave velocity a useful tool for cardiovascular surveillance in pre-dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3527-3532.	0.4	24
340	Metabolic Syndrome Is Associated With Coronary Artery Calcium in Asymptomatic White Brazilian Men Considered Low "Risk by Framingham Risk Score. <i>Preventive Cardiology</i> , 2007, 10, 141-146.	1.1	15
341	Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. <i>Atherosclerosis</i> , 2007, 194, 517-519.	0.4	26
342	High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men. <i>Atherosclerosis</i> , 2007, 195, e155-e160.	0.4	26

#	ARTICLE	IF	CITATIONS
343	The Progression and Impact of Vascular Calcification in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 340-346.	1.1	35
344	Relation of Uric Acid Levels to Presence of Coronary Artery Calcium Detected by Electron Beam Tomography in Men Free of Symptomatic Myocardial Ischemia With Versus Without the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2007, 99, 42-45.	0.7	45
345	Relation of Plasma Lipoprotein Levels With Low-Grade Inflammation in White Men Without Clinical Evidence of Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2007, 100, 450-454.	0.7	6
346	Combined Effect of High Low-Density Lipoprotein Cholesterol and Metabolic Syndrome on Subclinical Coronary Atherosclerosis in White Men Without Clinical Evidence of Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2007, 100, 840-843.	0.7	15
347	Relationship between White Blood Cell Count and Framingham Risk Score in Asymptomatic Men. <i>Archives of Medical Research</i> , 2007, 38, 386-391.	1.5	4
348	Difference in atherosclerosis burden in different nations and continents assessed by coronary artery calcium. <i>Atherosclerosis</i> , 2006, 187, 378-384.	0.4	43
349	Subclinical coronary atherosclerosis: Racial profiling is necessary!. <i>American Heart Journal</i> , 2006, 152, 819-827.	1.2	38
350	Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men. <i>International Journal of Cardiology</i> , 2006, 108, 68-75.	0.8	7
351	Increased level of cardiorespiratory fitness blunts the inflammatory response in metabolic syndrome. <i>International Journal of Cardiology</i> , 2006, 110, 224-230.	0.8	16
352	Association of Body Mass Index, Metabolic Syndrome, and Leukocyte Count. <i>American Journal of Cardiology</i> , 2006, 97, 835-838.	0.7	58
353	Association of Increased Cardiorespiratory Fitness with Low Risk for Clustering of Metabolic Syndrome Components in Asymptomatic Men. <i>Archives of Medical Research</i> , 2006, 37, 522-528.	1.5	26
354	Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. <i>American Journal of Cardiology</i> , 2005, 95, 865-868.	0.7	21
355	Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: Effects of simvastatin. <i>Lipids</i> , 2005, 40, 737-743.	0.7	18
356	The Association of Subclinical Coronary Atherosclerosis With Abdominal and Total Obesity in Asymptomatic Men. <i>Preventive Cardiology</i> , 2005, 8, 59-62.	1.1	16
357	Effects in post-menopausal women of transdermal estrogen associated with progestin upon the removal from the plasma of a microemulsion that resembles low-density lipoprotein (LDL). <i>Maturitas</i> , 2005, 50, 275-281.	1.0	9
358	Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2225-2232.	1.2	30
359	Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease. <i>Atherosclerosis</i> , 2004, 176, 397-403.	0.4	25
360	Clearance of a 3H-labeled chylomicron-like emulsion following the acute phase of myocardial infarction. <i>International Journal of Cardiology</i> , 2004, 93, 181-187.	0.8	3



#	ARTICLE	IF	CITATIONS
361	Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. <i>Atherosclerosis</i> , 2003, 166, 311-321.	0.4	30
362	Hypercholesterolemia Blunts Forearm Vasorelaxation and Enhances the Pressor Response During Acute Systemic Hypoxia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1660-1666.	1.1	15
363	Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. <i>Journal of Lipid Research</i> , 2003, 44, 464-469.	2.0	29
364	National alert campaign about increased cholesterol: determination of cholesterol levels in 81,262 Brazilians. <i>Arquivos Brasileiros De Cardiologia</i> , 2003, 80, 635-638.	0.3	28
365	Distribution of coronary artery calcium scores determined by ultrafast computed tomography in 2.253 asymptomatic white men. <i>Arquivos Brasileiros De Cardiologia</i> , 2003, 81 Suppl 7, 27-36.	0.3	1
366	LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. <i>Atherosclerosis</i> , 2002, 161, 447-453.	0.4	17
367	Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. <i>Atherosclerosis</i> , 2001, 154, 455-461.	0.4	19
368	Trends in the risk of mortality due to cardiovascular diseases in five Brazilian geographic regions from 1979 to 1996. <i>Arquivos Brasileiros De Cardiologia</i> , 2001, 77, 562-75.	0.3	10
369	Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 332-8.	0.3	26
370	Levels of lipoprotein (a) in pulmonary arterial hypertension. <i>Cardiology in the Young</i> , 2001, 11, 25-29.	0.4	3
371	Effect of Pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. <i>American Journal of Cardiology</i> , 2000, 85, 1163-1166.	0.7	44
372	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. <i>Arquivos Brasileiros De Cardiologia</i> , 2000, 75, 296-302.	0.3	3
373	Lipoprotein lipase does not affect lipoprotein (a) levels in normotriglyceridemic patients. <i>International Journal of Cardiology</i> , 1995, 50, 79-81.	0.8	2
374	III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 77, 1-48.	0.3	164
375	Distribuição dos escores de cálcio coronariano determinados pela tomografia ultrarápida em 2.253 homens brancos assintomáticos. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 81, 27-31.	0.3	6